Climb Bio Inc (CLYM) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Climb Bio Inc (CLYM) closed at USD 10.29 on 2026-10-14, a change of +394.7 % over the past year, with a market capitalization of USD 626.63M.

Climb Bio Inc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Climb Bio Inc key figures

Previous close

USD 10.29 (2026-10-14)

1-year change

+394.7 %

Market cap

USD 626.63M

Enterprise value

USD 444.82M

P/E ratio (trailing)

-12.54

P/E ratio (forward)

-10.88

EPS (trailing)

-0.87

EPS (forward)

-1.00

PEG ratio

n/a

Price to book

2.62

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.36

Employees

28

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Climb Bio Inc

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Climb Bio Inc and compare it with other stocks.